不知未来
2023-01-24
为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？
润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
左撇子0617
2023-01-24
左撇子0617
过来学习看看
共享快乐
2023-01-24
共享快乐
过来看看
Allen moft
2023-01-24
Allen moft
e
啊啦雷
2023-01-24
啊啦雷
po ho
啊啦雷
2023-01-24
啊啦雷
h h h h h
啊啦雷
2023-01-24
啊啦雷
h h h h
查看全部10条评论
APP内打开
发表看法
10
9
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":626565086,"tweetId":"626565086","gmtCreate":1674527174845,"gmtModify":1674528854669,"author":{"id":4110571816671610,"authorId":4110571816671610,"authorIdStr":"4110571816671610","name":"不知未来","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？</p></body></html>","htmlText":"<html><head></head><body><p>为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？</p></body></html>","text":"为什么上市以来一直下跌，市值一直萎缩，股价下跌80%是否公司出什么大事没发公告出来，还是人为问题？如：操纵杀跌？","highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":10,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/626565086","repostId":2294985825,"repostType":2,"repost":{"id":"2294985825","pubTimestamp":1672220164,"share":"https://www.laohu8.com/m/news/2294985825?lang=&edition=full","pubTime":"2022-12-28 17:36","market":"sh","language":"zh","title":"润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》","url":"https://stock-news.laohu8.com/highlight/detail?id=2294985825","media":"智通财经","summary":"智通财经APP讯，润迈德-B 公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。同时，caIMR系统作为全球领先的无介入微循环病变诊疗系统，突破性地实现了微血管功能的无创定量评估。caFFR系统和caIMR系统的联合诊断可定量评估心外膜下冠脉狭窄或微小动脉病变导致的心肌缺血，进行相应的治疗决策，这将推动冠脉介入精准医疗的发展。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02297\">润迈德-B</a>(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。</p><p>根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据的积累，caFFR系统有望替代导丝测量FFR成为指导血运重建的常规手段，推动心肌缺血的功能学评估在国内外的普及与应用。同时，caIMR系统作为全球领先的无介入微循环病变诊疗系统，突破性地实现了微血管功能的无创定量评估。 caFFR系统和caIMR系统的联合诊断可定量评估心外膜下冠脉狭窄或微小动脉病变导致的心肌缺血，进行相应的治疗决策，这将推动冠脉介入精准医疗的发展。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n润迈德-B(02297)：caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-28 17:36 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/853624.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，润迈德-B(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/853624.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02297":"润迈德-B","BK1100":"医疗保健设备"},"source_url":"http://www.zhitongcaijing.com/content/detail/853624.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2294985825","content_text":"智通财经APP讯，润迈德-B(02297)公布，集团的核心产品caFFR系统及caIMR系统被纳入《中国计算冠状动脉生理学检测技术专家共识》。根据该专家共识，caFFR系统无需导丝与血管扩张药物即可进行冠状动脉功能学评价，操作简单，易于学习，节省测量时间，拓宽了适用人群，降低了技术风险。大量的临床证据已经证明caFFR系统的诊断准确性、临床适应症及预后价值，更多的临床证据将会不断涌现。随着临床证据的积累，caFFR系统有望替代导丝测量FFR成为指导血运重建的常规手段，推动心肌缺血的功能学评估在国内外的普及与应用。同时，caIMR系统作为全球领先的无介入微循环病变诊疗系统，突破性地实现了微血管功能的无创定量评估。 caFFR系统和caIMR系统的联合诊断可定量评估心外膜下冠脉狭窄或微小动脉病变导致的心肌缺血，进行相应的治疗决策，这将推动冠脉介入精准医疗的发展。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1483,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":103,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":7844529,"gmtCreate":1674529825614,"gmtModify":1674529838782,"authorId":3496282891636458,"author":{"id":3496282891636458,"authorId":3496282891636458,"name":"左撇子0617","avatar":"https://static.tigerbbs.com/941ba0b6d933eb2d70ea344feb35d8a5","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"过来学习看看","text":"过来学习看看","html":"过来学习看看","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":7844545,"gmtCreate":1674530175605,"gmtModify":1674533304141,"authorId":4118901347312970,"author":{"id":4118901347312970,"authorId":4118901347312970,"name":"共享快乐","avatar":"https://static.tigerbbs.com/031a1d764d243beb971e11bdb712536a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"过来看看","text":"过来看看","html":"过来看看","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":7844568,"gmtCreate":1674530942588,"gmtModify":1674530955747,"authorId":4114797862927240,"author":{"id":4114797862927240,"authorId":4114797862927240,"name":"Allen moft","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">e</span>","text":"<span class=\"s1\">e</span>","html":"<span class=\"s1\">e</span>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":7844567,"gmtCreate":1674530938275,"gmtModify":1674530951624,"authorId":4103012405740810,"author":{"id":4103012405740810,"authorId":4103012405740810,"name":"啊啦雷","avatar":"https://static.tigerbbs.com/59d6bc0eecd5e2ab29d590759c3fdfd3","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">po ho</span>","text":"<span class=\"s1\">po ho</span>","html":"<span class=\"s1\">po ho</span>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":7844563,"gmtCreate":1674530820300,"gmtModify":1674530833564,"authorId":4103012405740810,"author":{"id":4103012405740810,"authorId":4103012405740810,"name":"啊啦雷","avatar":"https://static.tigerbbs.com/59d6bc0eecd5e2ab29d590759c3fdfd3","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">h h h h h</span>","text":"<span class=\"s1\">h h h h h</span>","html":"<span class=\"s1\">h h h h h</span>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":7844562,"gmtCreate":1674530812330,"gmtModify":1674530825660,"authorId":4103012405740810,"author":{"id":4103012405740810,"authorId":4103012405740810,"name":"啊啦雷","avatar":"https://static.tigerbbs.com/59d6bc0eecd5e2ab29d590759c3fdfd3","vip":1,"currentWearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.23","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":626565086,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">h h h h</span>","text":"<span class=\"s1\">h h h h</span>","html":"<span class=\"s1\">h h h h</span>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/626565086"}
精彩评论